Ureteral Stents Market

• Growing incidence of kidney diseases to boost market growth

The growing incidence of kidney diseases has a significant impact on the ureteral stents market. Kidney diseases such as kidney stones, urinary tract infections, tumors, and other urological disorders often require the placement of a ureteral stent. A ureteral stent is a flexible, hollow tube that is inserted into the ureter to help urine flow from the kidney to the bladder. Ureteral stents are used to treat a variety of conditions, including kidney stones, tumors, and strictures. 

The increasing prevalence of kidney diseases, particularly kidney stones, is one of the key drivers of the ureteral stents market. According to a report by the National Kidney Foundation, kidney stones affect about one in ten people at some point in their lives, and the incidence of kidney stones has been increasing over the past few decades. In addition, the increasing aging population is also contributing to the growth of the ureteral stents market. As people age, they are more likely to develop urological disorders that require the use of ureteral stents. 

Moreover, technological advancements in ureteral stent design and materials have also driven the growth of the ureteral stents market CAGR. These advancements have led to the development of stents with improved durability, biocompatibility, and ease of insertion, which has made them more attractive to both patients and healthcare providers.

Rising prevalence of kidney diseases is projected to propel worldwide ureteral stents market to expand during the projection period. For instance, the United States Renal Data System (USRDS) reports that there are around 786,000 people in the country who have end-stage renal disease (ESRD), of whom 71% require dialysis and 29% a kidney transplant. 

In the United States, 131,636 people have received an ESRD diagnosis in 2018, a 2.3% increase from 2017. Unadjusted ESRD incidence per million grew by 1.5% between 2017 and 2018, however adjusted ESRD incidence per million increased by just 0.2%. Also, According to USRDS Coordinating Center (CC), 14.9% of the adult population in the United States that were surveyed during 2015 and 2018 had chronic kidney disease (CKD) based on a low eGFR or proteinuria (on a single examination). 

According to the same organization, in 2018, the number of End-Stage Renal Disease (ESDR) incidents reported were 1,31,112 and in 2019, the number reached 1,34,608. which is anticipated to fuel significant growth of ureteral stents market revenue.

The Global Ureteral Stents Market Industry is projected to experience substantial growth over the next decade. With an estimated market value of 0.53 USD Billion in 2024, it is expected to reach approximately 0.97 USD Billion by 2035. This growth trajectory indicates a compound annual growth rate (CAGR) of 5.67% from 2025 to 2035, driven by factors such as increasing urological disorders, technological advancements, and enhanced healthcare access. The market's expansion reflects the growing recognition of the importance of effective urological treatments and the ongoing innovations in ureteral stent design and application.

Innovations in ureteral stent technology significantly enhance their effectiveness and patient comfort. Developments such as biocompatible materials and advanced coatings reduce complications like encrustation and infection. The Global Ureteral Stents Market Industry benefits from these advancements, as they lead to improved patient outcomes and satisfaction. As healthcare providers increasingly adopt these advanced stents, the market is projected to grow. The anticipated compound annual growth rate (CAGR) of 5.67% from 2025 to 2035 indicates a robust demand for technologically superior ureteral stents, which are becoming essential in modern urological practices.

The rising prevalence of urological disorders globally drives the demand for ureteral stents. Conditions such as kidney stones and urinary obstructions necessitate the use of stents for effective management. In 2024, the Global Ureteral Stents Market Industry is valued at approximately 0.53 USD Billion, reflecting the growing need for these medical devices. As the population ages and lifestyle factors contribute to urological issues, the market is expected to expand. This trend suggests a sustained increase in the adoption of ureteral stents, which are crucial for alleviating symptoms and preventing complications associated with these disorders.

Supportive regulatory frameworks and favorable reimbursement policies play a crucial role in the growth of the Global Ureteral Stents Market Industry. Governments and health authorities are increasingly recognizing the importance of urological health, leading to policies that facilitate the approval and reimbursement of ureteral stents. This regulatory environment encourages manufacturers to innovate and expand their product offerings. As reimbursement rates improve, healthcare providers are more likely to adopt ureteral stents as a standard treatment option, thereby driving market growth. The anticipated increase in market value to 0.97 USD Billion by 2035 reflects this positive trend.

The expansion of healthcare infrastructure globally facilitates better access to urological treatments, including ureteral stenting procedures. As hospitals and clinics enhance their capabilities, the Global Ureteral Stents Market Industry is poised for growth. Increased investment in healthcare facilities, particularly in developing regions, allows for more comprehensive urological care. This improved access is likely to result in higher rates of stent placements, as more patients can receive timely interventions for urological disorders. The market's growth trajectory is supported by these infrastructural developments, which aim to meet the rising demand for effective urological solutions.

Increased awareness regarding urological health among the general population contributes to the growth of the Global Ureteral Stents Market Industry. Educational campaigns by healthcare organizations promote early diagnosis and treatment of urological conditions, leading to higher rates of stent utilization. As patients become more informed about their health options, they are more likely to seek medical intervention for issues that may require stenting. This trend is expected to drive market growth, as proactive healthcare measures lead to a higher demand for ureteral stents, ultimately improving patient outcomes and quality of life.

Major market players are spending a lot of money on R&D to increase their product lines, which will help the ureteral stents market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the ureteral stents industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the ureteral stents industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, ureteral stents industry has provided treatment with some of the most significant benefits. The ureteral stents market major player such as Boston Scientific (US), Cook Medical (US), Allium Medical (Israel), and others are working to expand the market demand by investing in research and development activities.

The Boston Scientific Corporation was established in year 1979 and its headquarters is in Marlborough, Massachusetts, United States. The company is a medical device developer, producer, and marketer with products used in a variety of interventional medical specialties. Cardiovascular and cardiac rhythm management (CRM) products are the company's key products. Electrophysiology, pain treatment (neuromodulation), endoscopy, pelvic health, and urology are among the devices it produces. 

Biopsy forceps, coronary and urethral stents, catheters, defibrillators, pacemakers and needles are some of the company's diagnostic and treatment products. The company globally provides its products and services in more than 120 countries. The employee size of the company is 10,001+ employees. In June 2022, for its Tria Ureteral Stent, the first stent built with a patented surface technology intended to give protection against the accumulation from both urine calcium and magnesium salt deposits, Boston Scientific has been honoured with a Bronze Edison Award in the field of Science and Medicine.

Also, Allium Medical was established in year 2008 and its headquarters is in Haeshel St, Caesarea, Israel. The company develops, produces, and markets cutting-edge, long-lasting, fully covered, expandable, and retrievable stents for the treatment of various blockages in the GI and urinary tracts on a scale. In contrast to the usual practise of surgery or short-term solutions, Allium's distinctive stent solutions offer a less invasive, reversible alternative approach. 

With its extensive proven experience and usage, Allium is paving the way for patients and doctors to provide the next level of patient care. In May 2018, The China Food and Drug Administration (CFDA) has granted Allium Medical, an Israeli medical device firm that specialises in minimally invasive technologies and solutions, permission to commercialise its range of urology systems in China. In the Chinese urology sector, the company has an exclusive strategic partnership with a distribution company.